- Home
- ANNX vs XPOF Comparison
ANNX vs XPOF Comparison
Compare ANNX & XPOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- XPOF
- Stock Information
- Founded
- ANNX 2011
- XPOF 2017
- Country
- ANNX United States
- XPOF United States
- Employees
- ANNX N/A
- XPOF N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- XPOF Services-Misc. Amusement & Recreation
- Sector
- ANNX Health Care
- XPOF Consumer Discretionary
- Exchange
- ANNX Nasdaq
- XPOF Nasdaq
- Market Cap
- ANNX 253.8M
- XPOF 302.9M
- IPO Year
- ANNX 2020
- XPOF 2021
- Fundamental
- Price
- ANNX $3.09
- XPOF $7.80
- Analyst Decision
- ANNX Strong Buy
- XPOF Buy
- Analyst Count
- ANNX 4
- XPOF 7
- Target Price
- ANNX $13.00
- XPOF $12.93
- AVG Volume (30 Days)
- ANNX 2.4M
- XPOF 527.9K
- Earning Date
- ANNX 11-13-2025
- XPOF 11-06-2025
- Dividend Yield
- ANNX N/A
- XPOF N/A
- EPS Growth
- ANNX N/A
- XPOF N/A
- EPS
- ANNX N/A
- XPOF N/A
- Revenue
- ANNX N/A
- XPOF $316,841,000.00
- Revenue This Year
- ANNX N/A
- XPOF N/A
- Revenue Next Year
- ANNX N/A
- XPOF $2.86
- P/E Ratio
- ANNX N/A
- XPOF N/A
- Revenue Growth
- ANNX N/A
- XPOF N/A
- 52 Week Low
- ANNX $1.29
- XPOF $6.64
- 52 Week High
- ANNX $7.85
- XPOF $18.87
- Technical
- Relative Strength Index (RSI)
- ANNX 60.42
- XPOF 40.60
- Support Level
- ANNX $2.91
- XPOF $7.76
- Resistance Level
- ANNX $3.38
- XPOF $8.31
- Average True Range (ATR)
- ANNX 0.24
- XPOF 0.32
- MACD
- ANNX 0.02
- XPOF 0.02
- Stochastic Oscillator
- ANNX 61.87
- XPOF 31.63
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About XPOF Xponential Fitness Inc.
Xponential Fitness Inc is a curator of boutique fitness brands. Its diversified portfolio of brands includes Club Pilates, a Pilates brand in the United States; CycleBar, an indoor cycling brand in the United States; StretchLab, a concept offering one-on-one and group stretching services; Row House, a high-energy, low-impact indoor rowing workout; AKT, a dance-based cardio workout combining toning, interval and circuit training; YogaSix a franchised yoga brand; Pure Barre, a total body workout that uses the ballet barre to perform small isometric movements; Stride, a treadmill-based cardio and strength training concept; Rumble, a boxing-inspired full-body workout; and BFT, a functional training and strength-based program. Its key revenue source is franchise income.